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A B S T R A C T
Purpose: Epilepsy is associated with increased cardiovascular disease (CVD) morbidity and mortality.
The exact causes of this link are not clearly deﬁned. The role of antiepileptic drugs (AEDs) in inﬂuencing
CVD risk in patients with epilepsy remains controversial. A link between epilepsy, AEDs and cardiac
arrhythmias has been proposed and may be responsible for sudden unexpected death in epilepsy
(SUDEP).
Methods: We searched MEDLINE up to December 1, 2013 for relevant publications using combinations
of keywords. We also examined the reference list of articles identiﬁed by this search and selected those
we judged relevant. These were included in this narrative review.
Results: AEDs may exert both beneﬁcial and adverse cardiovascular effects. This narrative review
considers the inﬂuence of AEDs on some predictors of vascular risk [i.e. weight, insulin resistance,
metabolic syndrome, lipids, lipoprotein (a), C-reactive protein, homocysteine, vitamins, coagulation
factors, uric acid, carotid intima media thickness, markers of oxidative status and matrix
metalloproteinase-9]. Certain AEDs can also have pro-arrhythmic properties.
Conclusions: AEDs may exert different effects on various established and emerging predictors of vascular
risk. Furthermore, pharmacokinetic interactions between AEDs and drugs used to reduce vascular risk
(e.g. statins) need to be better documented.
Whether this knowledge, in terms of individualizing antiepileptic and CVD prevention treatment, will
prove to be relevant in clinical practice remains to be established.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Epilepsy is a chronic neurological disorder characterized by
predisposition to recurrent seizures.1 Epidemiological studies have
shown that patients with epilepsy have an increased mortality
compared with the general population, with cardiovascular
disease (CVD) being a signiﬁcant cause of death.2–4 Furthermore,
epilepsy has been associated with a higher risk of CVD-related
events.4–6 Of note, seizures may occur following cerebrovascular
events and especially after major strokes and sinus thrombosis.7 In
addition, patients with autoimmune diseases such as systemic
lupus erythematosus, Sjogren’s syndrome, Crohn’s and Behcet’s* Corresponding author at: Department of Clinical Biochemistry
(Vascular Disease Prevention Clinics), Royal Free Hospital, Pond Street,
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1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights redisease, which have been also linked to increased CVD risk,8,9 can
present with epilepsy.10 Seizures may also be the ﬁrst clinical
manifestation of brain arteriovenous malformations, especially
when they are located in the frontal and temporal lobes.11Whether
established vascular risk factors (e.g. hypertension and activated
hemostasis) and more speculative ones (e.g. lipid oxidation)11 play
a signiﬁcant role in bleeding or thrombus formation related to such
malformations is not clearly established.
The association between epilepsy and CVD morbidity and
mortality is not clearly deﬁned. In this context, antiepileptic drugs
(AEDs) may differentially inﬂuence CVD risk in patients with
epilepsy. Furthermore, a link between epilepsy, AEDs and cardiac
arrhythmias has also been proposed that may be responsible for
sudden unexpected death in epilepsy (SUDEP) in such patients.
Another possible explanation for the link between epilepsy and
CVD is that patients with epilepsy are more likely to be cigarette
smokers compared with individuals without epilepsy.12,13 Smok-
ing is a predictor of arterial stiffness14 that affects all arteries.15served.
Table 1
Effects of antiepileptic drugs on cardiac arrhythmias and sudden
unexpected death in epilepsy.
AEDs Effects
Carbamazepine Proarrhythmic effects, SUDEP
Phenytoin Proarrhythmic effects
Lamotrigine SUDEP
AEDs: antiepileptic drugs; SUDEP: sudden unexpected death in
epilepsy.
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unhealthy dietary habits.12,13 This behaviour predisposes them to
increased CVD risk as both physical activity and a balanced diet,
such as the Mediterranean diet, have been associated with
improvements in several CVD risk factors.16,17
Recently leucocyte adhesion in the brain parenchyma has been
related to seizure induction.18 In this context, the development of
interventions targeting this brain leucocyte trafﬁcking may
represent a novel therapeutic strategy for epilepsy.19 Seizures
cause endothelial sloughing from cerebral vessels resulting in
brain-derived circulating endothelial cells (BCECs) in the fraction
of peripheral blood mononuclear cells.20 BCECs are possible early
indicators of cerebral vascular damage after epileptic seizures.20
This narrative review considers the inﬂuence of AEDs on
arrhythmias and SUDEP as well as on some predictors of vascular
risk [i.e. weight, insulin resistance, metabolic syndrome (MetS),
lipids, lipoprotein (a) (LP(a)), C-reactive protein (CRP), homocys-
teine (Hcy), vitamins, coagulation factors, uric acid, carotid intima
media thickness (cIMT), markers of oxidative status and matrix
metalloproteinase-9 (MMP-9)].
2. Search methods
We searched MEDLINE up to December 1, 2013 for relevant
publications using combinations of the following keywords:
epilepsy, antiepileptic drugs, arrhythmias, sudden unexpected
death, weight, insulin resistance, metabolic syndrome, lipids,
lipoprotein (a), C-reactive protein, homocysteine, folate, vitamin
B6, vitamin B12, vitamin D, plasminogen activator inhibitor-1,
tissue plasminogen activator antigen, von Willebrand factor,
ﬁbrinogen, coagulation factors, uric acid, carotid intima media
thickness, markers of oxidative status and matrix metalloprotei-
nase-9.
We also examined the reference list of articles identiﬁed by this
search and selected those we judged relevant. These were included
in this narrative review. Overall, we concentrated on recent
publications (the vast majority are dated after 1990).
3. Epilepsy, AEDs and SUDEP
Patients with epilepsy may be susceptible to cardiac arrhyth-
mias due to both genetic predisposition and/or seizure-induced
chronic autonomic dysfunction.21,22 Furthermore, such arrhyth-
mias could be aggravated by the presence of coronary heart disease
(CHD) and ischaemia due to atherosclerosis. Certain AEDs such as
phenytoin and carbamazepine have also been shown to exert pro-
arrhythmic effects.22 In addition, epileptic seizures have been
reported to induce cardiac ischaemia both via chronic and acute
effects on the heart [e.g. impaired heart rate variability, cardiac
ﬁbrosis, ST-segment depression and increased heart rate].22,23
These effects have been particularly studied in cases of SUDEP
which accounts for 5–30% of deaths in patients with epilepsy.24
SUDEP has been associated with ﬁbrotic changes in the deep and
subendocardial myocardium, possibly attributed to seizure-
induced myocardial ischaemia, which in conjunction with
seizure-derived arrhythmias may result in cardiac death.23
Alterations in electrolytes and blood pH together with the release
of catecholamines might facilitate arrhythmias.25
There is also evidence that cardiac troponin-I (cTNI) release of
unknown origin occurs in patients without cardiac symptoms but
with generalized seizures.26 This cTNI rise was more prominent in
patients with vascular risk factors (e.g. hypertension, hypercho-
lesterolaemia or diabetes).26
Although the exact pathogenesis of SUDEP remains unknown,
signiﬁcant risk factors include onset of epilepsy at an early age,
seizure recurrence, polytherapy with AEDs and frequent dosechanges.27–30 According to the International League Against
Epilepsy (ILAE) Commission on Epidemiology/Subcommission on
Mortality, decreasing the frequency of generalized tonic-clonic
seizures is a priority, even more important than reducing the
number of AEDs.31,32 Age and gender differences have also been
reported; women have a higher prevalence rate of SUDEP23,29 but it
usually occurs later in life than in men (mean age 52 years in
women vs 38 years in men).23 It is not known if this gender
difference is related to hormonal changes (i.e. menopause).
Whether established vascular risk factors are more commonly
present in cases of SUDEP has not been clariﬁed yet.33
Of note, although some studies reported an association between
carbamazepine or lamotrigine treatment and SUDEP,34,35 evi-
dence-based data to support a causative relationship between the
use of any particular AED and SUDEP is lacking.28,36 In contrast,
subtherapeutic AEDs levels are implicated in SUDEP24 and seizure
control with as few AEDs as necessary is regarded as important for
SUDEP prevention.28,36 Finally, apart from cardiac dysfunction,
SUDEP has been related to genetic predisposition, mental
retardation, neurogenic pulmonary oedema, apnoea and sleep
disorders.36–38 Psychiatric illness and psychotropic drug adminis-
tration have been associated with the risk of SUDEP in some but not
all studies.29,39,40 It is possible that these patients are more likely to
be institutionalized, looked after by carers and they may have
relationship issues. Whether these factors affect lifestyle and drug
compliance remains to be established.
Overall, signiﬁcant risk factors for SUDEP involve early onset of
epilepsy, seizure frequency and polytherapy with AEDs. Further-
more, certain AEDs (e.g. carbamazepine and phenytoin) may exert
pro-arrhythmic properties. Table 1 summarizes these effects.
4. Effects of AEDs on weight, insulin resistance and MetS
AEDs are a diverse group of anticonvulsant agents.41 Among
them, valproic acid (valproate), carbamazepine, pregabalin,
gabapentin and vigabatrin have been associated with weight
increase.42–45 Possible mechanisms involved in AEDs-induced
weight gain include leptin and insulin resistance, hyperinsulinae-
mia and increased food intake (e.g. carbohydrate craving).46–51 In
this context, obese patients with epilepsy on valproic acid were at a
higher risk of developing MetS compared with otherwise healthy
obese individuals.52 Furthermore, non-alcoholic fatty liver disease
(NAFLD), the hepatic manifestation of MetS, was diagnosed by
ultrasound measurement in patients on valproic acid, carbamaze-
pine and lamotrigine monotherapy (in 60.9, 22.7 and 8.7% of
treated patients, respectively).53 However, there were no differ-
ences in insulin resistance between the study groups and TC, LDL-
C, HDL-C and gamma-glutamyltransferase were signiﬁcantly
higher in the carbamazepine group.53 Of note, valproic acid
monotherapy has been related to NAFLD development even in
adolescents.54 These associations are of clinical importance as
MetS and NAFLD are linked to increased CVD risk.55–57
Lamotrigine, levetiracetam and phenytoin are considered
weight neutral, whereas felbamate, topiramate and zonisamide
were reported to decrease weight.41,41,58 However, there are also
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For example, phenytoin treatment, although regarded as weight
neutral, has also been associated with weight gain45 and insulin
resistance.59 Furthermore, no signiﬁcant differences in body mass
index (BMI) between men with epilepsy on valproic acid,
carbamazepine or oxcarbazepine monotherapy and individuals
without epilepsy were reported.60 In another study, patients with
epilepsy on levetiracetam, carbamazepine or lamotrigine mono-
therapy for at least 6 months had signiﬁcantly greater BMI
compared with controls in both genders.61 However, when
analyzed separately according to the antiepileptic treatment, the
differences were signiﬁcant only for women on carbamazepine or
on lamotrigine compared with controls.61
As weight gain and obesity are associated with CVD risk,62,63 the
weight-related effects of AEDs may need to be considered when
selecting individual antiepileptic therapy. This is especially true for
patients who are already overweight/obese or at high CVD risk [e.g.
those with MetS or type 2 diabetes mellitus (T2DM)].
Overall, AEDs may differentially inﬂuence weight in patients
with epilepsy, subsequently affecting the development of insulin
resistance, MetS and NAFLD. Table 2 summarizes these effects.
5. Effects of AEDs on lipid and lipoprotein (a) [Lp (a)] levels
In relation to their effects on lipid metabolism, AEDs are either
enzyme-inducers, which enhance hepatic P450 cytochrome
system activity, leading to increased cholesterol synthesis, or,
enzyme-inhibitors, which exert the opposite action.64 Phenytoin,
phenobarbital, carbamazepine and primidone are enzyme-induc-
ing AEDs, whereas valproate, lamotrigine and levetiracetam are
enzyme-inhibitors.64 Accordingly, in patients receiving phenytoin,
total cholesterol (TC), triglycerides (TG) and low density lipopro-
tein cholesterol (LDL-C) levels were signiﬁcantly increased
compared with both controls and those on valproate.59 Further-
more, carbamazepine monotherapy has been associated with
increases in TC, LDL-C, high density lipoprotein cholesterol (HDL-
C) and TG concentrations,61,65–67 although conﬂicting results have
been reported.60 Interestingly, a gender effect was observed, with
more pronounced increases in both HDL-C and LDL-C levels in
women with epilepsy.67
Valproate-treated patients were reported to have lower TC,
LDL-C and HDL-C levels compared with subjects without epilep-
sy50,66; TG concentrations were either lower66 or higher than
controls.50 In patients with epilepsy both levetiracetam and
lamotrigine monotherapy did not alter TC, LDL-C and HDL-C
levels,61 although levetiracetam was shown to signiﬁcantly
increase LDL-C concentrations in a recent study.68 Women on
valproate had lower HDL-C concentrations compared with thoseTable 2
Effects of antiepileptic drugs on weight, insulin resistance and metabolic syndrome.
AEDs Effects
Valproic acid (valproate) Weight increase, MetS, NAFLD,
insulin resistance
Carbamazepine Weight increase, NAFLD
Pregabalin Weight increase
Gabapentin Weight increase
Vigabatrin Weight increase
Lamotrigine Weight neutral, NAFLD
Levetiracetam Weight neutral
Phenytoin Weight neutral/increase, insulin resistance
Felbamate Weight decrease
Topiramate Weight decrease
Zonisamide Weight decrease
AEDs: antiepileptic drugs; MetS: metabolic syndrome; NAFLD: non-alcoholic fatty
liver disease.on carbamazepine, lamotrigine or topiramate,69 higher TG and
lower TC and LDL-C levels compared with those on carbamaze-
pine70 and lower TC, LDL-C and HDL-C concentrations compared
with those on lamotrigine.71
Replacement of carbamazepine with oxcarbazepine, apart from
normalization of the hepatic P450 cytochrome system activity (as
assessed by changes in half-life levels and clearance of antipyrine),
resulted in a signiﬁcant decrease in TC levels, although HDL-C and
TG concentrations remained unchanged.72 In contrast, oxcarba-
zepine monotherapy was recently reported to signiﬁcantly
increase LDL-C levels in another study.68 Furthermore, switching
from either phenytoin or carbamazepine to either lamotrigine or
levetiracetam monotherapy produced signiﬁcant decreases in TC,
TG and non-HDL-C levels in patients with epilepsy [p < 0.0001 for
all comparisons].73 A modest but signiﬁcant decrease in HDL-C
concentrations was also observed in patients who switched from
carbamazepine to either lamotrigine or levetiracetam monother-
apy [mean reduction = 6 mg/dl; p = 0.001].73
Carbamazepine monotherapy has been associated with in-
creased Lp (a) levels.65 Interestingly, in patients with epilepsy who
stopped carbamazepine, Lp (a) concentrations decreased signiﬁ-
cantly [30.6%; p = 0.0004].73 The effects of phenobarbital,
carbamazepine and valproate on Lp (a) levels have been studied
mainly in children with reports of increased concentrations in
some but not all studies.74–76
As lipid abnormalities are associated with increased CVD risk,
applying lifestyle measures and the use of lipid lowering drugs
may be beneﬁcial in patients with epilepsy, especially if long-term
compliance is maintained.77 The clinical relevance of decreasing
high circulating levels of Lp (a) is debated.78 However, it has been
suggested that the co-administration of statins with enzyme-
inducing AEDs may reduce statin effectiveness in achieving LDL-C
targets.79,80 The efﬁcacy of other drugs used in patients at risk of
vascular disease (e.g. antihypertensives and anticoagulants) may
be affected by AEDs.79 Studies have shown that phenytoin reduced
the efﬁcacy of several statins (e.g. atorvastatin, ﬂuvastatin and
simvastatin) leading to the administration of the highest doses
without successful control of TC.81,82 Therefore, the use of enzyme-
inducing AEDs may require higher doses of statins compared with
AEDs that inhibit or do not inﬂuence hepatic enzymes involved in
statin metabolism. However, data are scarce in this ﬁeld.64 The
combination of ezetimibe with a statin may provide the additional
lipid-lowering effect needed to reach LDL-C goals without using
the highest dose of statins.83 No studies that assessed the
pharmacokinetics of ezetimibe and AEDs were found. Pharmaco-
kinetic interactions may affect the metabolism of drugs that
inﬂuence vascular risk (e.g. losartan).84,85 A more detailed
discussion of these issues is beyond the scope of this review.
Overall, certain AEDs may increase lipids and Lp (a) levels,
whereas others may not. Table 3 summarizes these effects.Table 3
Effects of antiepileptic drugs on lipids and lipoprotein (a).
AEDs Effects
Valproic acid (valproate) Decreases in TC, LDL-C and HDL-C; TG
either decreased or increased
Increases in Lp (a)
Carbamazepine Increases in TC, TG, LDL-C and HDL-C
Increases in Lp (a)
Oxcarbazepine Increases in LDL-C, decreases in TC
Lamotrigine No changes
Levetiracetam Increases in LDL-C
Phenytoin Increases in TC, TG and LDL-C
Phenobarbital Increases in Lp (a)
AEDs: antiepileptic drugs; TC: total cholesterol; TG: triglycerides; LDL-C: low
density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; Lp (a):
lipoprotein (a).
Table 4
Effects of antiepileptic drugs on C-reactive protein, homocysteine, vitamins and
coagulation factors.
AEDs Effects
Valproic acid (valproate) Elevated CRP, Hcy, vitamin B12 and
ﬁbrinogen levels
Reduced folate and vitamin B6 levels
Increased vitamin B12 levels
Carbamazepine Elevated CRP, Hcy and ﬁbrinogen levels
Reduced folate, vitamin B6 and B12 levels
Increased vW factor activity
Lamotrigine Elevated CRP levels
Neutral on Hcy levels
Phenytoin Elevated CRP and Hcy levels
Reduced folate and vitamin B6 levels
Oxcarbazepine Elevated Hcy levels
Reduced folate levels
Phenobarbital Elevated Hcy levels
Reduced folate levels
Topiramate Elevated Hcy levels
Reduced folate levels
Levetiracetam Elevated or normal Hcy levels
CRP: C-reactive protein; Hcy: homocysteine; vW: von Willebrand.
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CRP is considered a marker of atherosclerosis86,87 and a
predictor of vascular risk.88–90 Therefore, the effects of AEDs on
CRP levels are important. Patients with epilepsy on several AEDs
(mostly valproate, carbamazepine, lamotrigine and phenytoin)
were reported to have higher serum CRP concentrations compared
with individuals without epilepsy.91 Furthermore, in people with
epilepsy, switching from either phenytoin or carbamazepine to
either lamotrigine or levetiracetam monotherapy was associated
with a signiﬁcant 31.4% reduction in CRP levels (p = 0.027).73 Of
note, this change in CRP concentrations correlated with signiﬁcant
reductions in Lp (a) (r = 0.43; p = 0.002) and HDL-C levels
(r = 0.327; p = 0.023) observed in those patients who stopped
carbamazepine.73
High levels of Hcy (i.e. hyperhomocysteinemia) are associated
with hypercoagulability92 and vascular disease risk.93 Further-
more, increased Hcy concentrations were shown to enhance
seizure activity.94 In this context, it has been suggested that Hcy is
pro-convulsant and may inﬂuence the response to AEDs.94 Several
drugs (e.g. antihypertensive, lipid lowering and hypoglycemic)
may inﬂuence circulating Hcy concentrations, as reported in a
meta-analysis.95 Treatment with carbamazepine, oxcarbazepine,
valproate, phenytoin, phenobarbital, levetiracetam or topiramate
has been associated with elevated Hcy levels.68,91,96–100 In
contrast, lamotrigine was found neutral with regard to Hcy
concentrations.97 However, conﬂicting results exist for carbamaz-
epine, valproate and levetiracetam.96,97,100,101 Interestingly,
patients on phenytoin monotherapy had signiﬁcantly higher Hcy
levels compared with patients on other AEDs (i.e. carbamazepine,
valproate and lamotrigine) or with patients on polytherapy.101
Furthermore, in individuals with epilepsy who stopped phenytoin,
Hcy concentrations decreased signiﬁcantly (p = 0.005), whereas in
those taken off carbamazepine no signiﬁcant changes were
found.73 Only patients on phenytoin had higher, although not
signiﬁcant, baseline Hcy levels compared with controls. These
observations highlight the need to establish the importance of
screening Hcy concentrations both before and during antiepileptic
therapy. Furthermore, genetic polymorphisms of the methylene-
tetrahydrofolate reductase (MTHFR) enzyme activity may affect
Hcy concentrations in patients with epilepsy; the CT677/AC1298
and TT677/AA1298 diplotypes have been associated with the
presence of hyperhomocysteinemia in epileptic patients on
enzyme-inducing AEDs, whereas the CC677/AA1298 diplotype
was more frequent in controls.102 Such polymorphisms may also
inﬂuence the response to folate supplementation; epileptic
patients on enzyme-inducing AEDs with the MTHFR677TT/
1298AA polymorphism, although having normal plasma folate
and Hcy levels following 1 month of folate supplementation (5 mg/
day), exhibited hyperhomocysteinemia at 6 months.103
The mechanism by which AEDs increase Hcy concentrations
may involve the depletion of folate, vitamins B6 and B12 [i.e.
cofactors in the metabolism of homocysteine].99,101 In this context,
treatment with several AEDs has been associated with reduced
folate [phenytoin, phenobarbital, valproate, topiramate, carba-
mazepine and oxcarbazepine],68,91,98,99,104,105 vitamin B6 [phe-
nytoin, valproate and carbamazepine]99 and B12 levels
[carbamazepine].98 In contrast, valproate was shown to increase
vitamin B12 levels.106,107 Of note, in patients with epilepsy on
phenytoin, valproate or carbamazepine monotherapy, serum
folate and vitamin B12 levels did not differ between those with
and those without CVD.108 Whether AEDs-induced changes in
these vitamin levels are translated to a higher risk of CVD events
remains to be established. Furthermore, the clinical relevance of
multivitamin supplementation in CVD risk reduction remainscontroversial.109 Nevertheless, some, but not all, investigators
support the use of multivitamin supplementations in patients with
epilepsy on AEDs,110–112 along with a ketogenic diet which is
known to exert antiseizure effects.113 Furthermore, in order to
prevent spontaneous abortion and congenital malformations,
women with epilepsy who might become pregnant are recom-
mended to receive at least 0.4 mg/day folate supplementation,114
especially those taking valproate.115 Attention should be paid in
patients on phenytoin, as folate supplementation increases the
metabolism of phenytoin, thus decreasing its serum concentration
to subtherapeutic levels.116
Elevated Hcy levels have been related to increased plasminogen
activator inhibitor-1, tissue plasminogen activator antigen, von
Willebrand (vW) factor and ﬁbrinogen levels.117 Patients with
epilepsy on carbamazepine or valproate monotherapy were
reported to have signiﬁcantly higher ﬁbrinogen concentrations
compared with controls.118 Patients treated with carbamazepine
had also higher vW factor activity levels compared with the control
group.118 In general, valproate treatment has been associated with
coagulopathies [e.g. acquired vW disease and thrombocytope-
nia].119,120 Therefore, impaired ﬁbrinolysis and enhanced coagulo-
pathy may represent another possible mechanism of AED-induced
hyperhomocysteinemia. However, in one study phenytoin therapy
was shown to reduce ﬁbrinogen levels,121 despite increasing Hcy
levels in other reports.99,101
Interestingly, enzyme-inducing AEDs (e.g. carbamazepine and
phenytoin) have been associated with increased bone turn-
over122,123 and fracture rates.123 These effects may partly be
attributed to AEDs-induced reduction in 25-hydroxyvitamin D
levels.124 Furthermore, vitamin D has been reported to exert
anticonvulsant properties, a ﬁnding that supports the prophylactic
use of vitamin D in patients with epilepsy on AEDs.125 The possible
link between vitamin D deﬁciency and atherosclerosis126,127
should also be considered in patients with epilepsy.
Overall, AEDs can inﬂuence CRP, Hcy, vitamins and coagulation
factors in patients with epilepsy. Table 4 summarizes these effects.
7. Effects of AEDs on uric acid, cIMT and markers of oxidative
status
Elevated levels of serum uric acid (SUA) have been associated
with CVD risk,56,128–130 a ﬁnding at least partly attributed to its
pro-inﬂammatory and pro-oxidant properties.129,130 In
this context, valproate monotherapy has been associated with
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oin monotherapy were reported to decrease SUA concentra-
tions.132
Several other drugs may inﬂuence SUA levels. Diuretics and b-
blockers have been reported to increase SUA concentrations.130 In
contrast, angiotensin II receptor antagonists (i.e. losartan), calcium
channel blockers (i.e. amlodipine), lipid lowering (i.e. atorvastatin,
simvastatin and fenoﬁbrate), weight reducing (i.e. orlistat and
sibutramine) and hypoglycaemic agents (i.e. metformin and
thiazolidinediones) have been shown to reduce SUA levels.130–
140 Based on the above data, it seems reasonable to suggest the
screening of SUA concentrations during antiepileptic therapy,
especially in patients on valproate. Furthermore, certain SUA
lowering agents may be preferred in those patients, in the presence
of other CVD risk factors (i.e. hypertension, dyslipidaemia, obesity
and T2DM).cIMT is an indicator of vascular risk.141 It is therefore of
interest that carbamazepine, phenytoin and valproic acid but not
lamotrigine monotherapy, signiﬁcantly increased cIMT.142 Fur-
thermore, cIMT was signiﬁcantly thicker in men than in women
with epilepsy.91 In the same study, apart from age, gender and
oxidative stress, duration of AED therapy was independently
associated with cIMT,91 thus suggesting that long-term exposure
to AEDs may be implicated in the development of atherosclerosis.
However, conﬂicting data also exist.143 Of note, in some studies
signiﬁcant increases in cIMT have been observed in children with
epilepsy on valproic acid compared with healthy children, despite
no differences in lipid proﬁles.144
Oxidative stress contributes to the progression of atherosclero-
sis145,146 and the development of CVD.147 Several biomarkers of
oxidative status are reported to predict CVD risk.148,149 However,
the role of antioxidant multivitamins supplementation on CVD risk
reduction remains controversial.109 In this context, valproate,
carbamazepine and phenobarbital treatment has been associated
with elevated levels of oxidative stress biomarkers (i.e. oxidized-
LDL, malondialdehyde, thiobarbituric reactive substances, lipid
hydroperoxide and asymmetric dimethylarginine) and decreased
total antioxidant capacity.91,106,118,131,150,151 However, available
data regarding the effects of AEDs on oxidative stress markers are
scarce and therefore no conclusions can be made.
Overall, AEDs may differentially affect SUA, cIMT and oxidative
stress markers in patients with epilepsy. Table 5 summarizes these
effects.
8. Matrix metalloproteinase-9 (MMP-9) and epilepsy
MMP-9 may contribute to arterial aneurysm formation and
atherosclerosis [e.g. plaque development and destabilization].152
In epilepsy animal models MMP-9 induction is associated with
homeostatic synaptic plasticity.153 Furthermore, MMP-9 was up-
regulated in the hippocampal dentate gyrus after kainate-
mediated seizures.154 Therefore, it has been hypothesized thatTable 5
Effects of antiepileptic drugs on uric acid, carotid intima-media thickness and
oxidative stress markers.
AEDs Effects
Valproic acid (valproate) Elevated SUA levels
Increased cIMT and oxidative stress markers
Reduced total antioxidant capacity
Carbamazepine Reduced SUA levels
Increased cIMT and oxidative stress markers
Reduced total antioxidant capacity
Phenytoin Reduced SUA levels
Increased cIMT
Phenobarbital Increased oxidative stress markers
Reduced total antioxidant capacity
SUA: serum uric acid; cIMT: carotid intima-media thickness.MMP-9 may be a therapeutic target for epilepsy.155 In this context,
statins (e.g. atorvastatin and lovastatin) have been recognized as
drugs that may exert anti-seizure effects.156 In turn, these drugs
(e.g. simvastatin) decrease MMP-9 activity.157 We did not ﬁnd any
literature regarding AEDs and MMP-9 activity. The above
mentioned ﬁndings link the aetiology of atherosclerosis with that
of epilepsy, as well as the treatment of vascular disease (i.e. with
statins) with a potential anti-epileptogenic effect. Of note, statin
use was shown to decrease the risk of hospitalization for
epilepsy.158 However, the effects of statins on epilepsy remain a
subject of debate.159
9. Conclusions
Evidence of a link between epilepsy and increased CVD
morbidity and mortality, has been available for several decades.160
Despite that, there is still a substantial need for deﬁnitive
recommendations to optimize prevention for these patients.
Earlier studies are limited; for example, several AEDs included
in the present review were not available then. Furthermore,
emerging vascular risk factors were often not considered and
established vascular risk factors were less commonly assessed.
Also, some drugs currently used for prevention of vascular disease
were not available and treatment targets were markedly different.
Even diagnostic tools for vascular disease were less advanced.
It is difﬁcult to assess vascular risk in patients with epilepsy
because the excess risk has not been deﬁnitively quantiﬁed or
recognized by the guidelines of learned societies. We suggest the
usual risk assessment with consideration that an additional risk
may exist in patients with epilepsy. The choice of AEDs may also
need to be considered in patients with metabolic or other vascular
risk factors. In this context, the present review discusses the
properties of AEDs that may not be favourable for patients already
at a higher risk of vascular events.
AEDs may exert different effects on various established and
emerging predictors of vascular risk [i.e. weight, lipids, Lp (a), CRP,
Hcy, vitamins, coagulation factors, uric acid, markers of oxidative
status and MMP-9]. Furthermore, pharmacokinetic interactions
between AEDs and drugs used to reduce vascular risk (e.g. statins)
need to be better documented. Whether this knowledge, in terms
of individualizing antiepileptic and CVD prevention treatment, will
prove to be relevant in clinical practice remains to be established.
Patients with epilepsy may represent another population with
high vascular risk; a fact possibly not yet fully perceived by health
care providers.
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